|Isis Innovation||Head of technology Transfer||Royaume-Uni|
Are universities a short-term or long term partner for spin-offs?
Dr Paul Ashley
After graduating from the University of Leeds with an honours degree in zoology, Paul worked as a curator for SeaLife Centres public aquariums. A return to academia followed with an MRC and industry sponsored PhD CASE studentship studying behavioural and physiological correlates of stress and depression. After completing his PhD, Paul took up a postdoctoral research fellow position at the University of Liverpool, conducting behaviour and neurophysiology research.
Paul then became the CEO of a spin-out company, commercialising remote monitoring and biotelemetry technology developed at the Defence Science Technology Laboratory. Following this, Paul took up a role at AstraZeneca as a member of the management team at the company’s environmental risk assessment facility. Here, Paul was responsible for the commercial development of a business with both internal and external customers. Paul joined Oxford University Innovation as a Deputy Head of Technology Transfer in July 2011. Paul runs a team of life science Technology Transfer Managers with a broad range of commercial and scientific experience, including drug development, medical technologies, immunology, genetics, biomarkers, vaccines, biochemistry and cell biology. Notable commercialisation projects include a strategic role in a vaccine joint venture, the creation of number of spin out companies in the fields of gene therapy, vaccine production and medical devices and completion of a range of life science technology licensing agreements. Paul is the relationship manager for a number of important charitable funders and partners.